- Home
- SAIH vs CLDI Comparison
SAIH vs CLDI Comparison
Compare SAIH & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAIH
- CLDI
- Stock Information
- Founded
- SAIH 2019
- CLDI 2014
- Country
- SAIH Singapore
- CLDI United States
- Employees
- SAIH N/A
- CLDI N/A
- Industry
- SAIH
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SAIH
- CLDI Health Care
- Exchange
- SAIH NYSE
- CLDI Nasdaq
- Market Cap
- SAIH 12.3M
- CLDI 10.2M
- IPO Year
- SAIH N/A
- CLDI N/A
- Fundamental
- Price
- SAIH $7.20
- CLDI $0.23
- Analyst Decision
- SAIH
- CLDI Strong Buy
- Analyst Count
- SAIH 0
- CLDI 1
- Target Price
- SAIH N/A
- CLDI $10.00
- AVG Volume (30 Days)
- SAIH 20.2K
- CLDI 1.8M
- Earning Date
- SAIH 04-28-2025
- CLDI 08-12-2025
- Dividend Yield
- SAIH N/A
- CLDI N/A
- EPS Growth
- SAIH N/A
- CLDI N/A
- EPS
- SAIH N/A
- CLDI N/A
- Revenue
- SAIH $5,543,000.00
- CLDI N/A
- Revenue This Year
- SAIH N/A
- CLDI N/A
- Revenue Next Year
- SAIH N/A
- CLDI N/A
- P/E Ratio
- SAIH N/A
- CLDI N/A
- Revenue Growth
- SAIH N/A
- CLDI N/A
- 52 Week Low
- SAIH $3.00
- CLDI $0.20
- 52 Week High
- SAIH $26.98
- CLDI $3.89
- Technical
- Relative Strength Index (RSI)
- SAIH N/A
- CLDI 21.13
- Support Level
- SAIH N/A
- CLDI $0.31
- Resistance Level
- SAIH N/A
- CLDI $0.33
- Average True Range (ATR)
- SAIH 0.00
- CLDI 0.04
- MACD
- SAIH 0.00
- CLDI -0.01
- Stochastic Oscillator
- SAIH 0.00
- CLDI 14.83
About SAIH SAIHEAT LIMITED
Saiheat Ltd develops technologies for the Computing Center Ecosystem (ACCE), a next-gen computing center featuring high-performance servers, liquid cooling, and systems for capturing and recycling computing heat. It aims to reduce the carbon footprint of Bitcoin mining and AI operations. The Company has four reportable segments: equipment sales, hosting, mining pool business, and mining.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.